期刊文献+

铝佐剂吸附CpG ODN增强重组乙肝疫苗免疫效应 被引量:4

CpG ODN adsorbed by aluminum adjuvant enhances the immune effect of recombinant hepatitis B vaccine
下载PDF
导出
摘要 目的探索新佐剂CpG ODN在重组乙肝疫苗中的免疫效应及吸附状态。方法 CpG ODN佐剂与重组乙肝疫苗混合免疫小鼠,收集小鼠血清检测。通过免疫小鼠后的体液和细胞免疫应答水平来评价双佐剂乙肝疫苗对重组乙肝疫苗的增强作用。CpG ODN佐剂与乙肝疫苗在不同温度条件下混合吸附,计算在不同吸附时间下CpG ODN佐剂在乙肝疫苗中的吸附率。结果CpG ODN佐剂可以提高重组乙肝疫苗在体液及细胞中的免疫效果。CpG ODN佐剂在室温条件下1 h即可在乙肝疫苗中达到吸附平衡,于2~8℃放置5 d的条件下其吸附率约在50%左右。结论 CpG ODN能够增加乙肝疫苗的免疫应答,其免疫效果可提高5倍以上。 To investigate the adsorption state and immunological effects of CpG ODN adjuvant in hepatitis B vaccine, Balb/c mice were vaccinated by HBV vaccine and CpG ODN adjuvant. Humoral immunity titers and cellular immunity were detected to evaluate the immunogenicity of vaccines adjuvanted with CpG ODN.Furthermore, CpG ODN adsorption rates in different conditions were calculated. Data showed that CpG ODN could significantly increase the cellular and humoral immune effect of HBV vaccine in mice. When CpG ODN(500 μg/ml) was mixed and stored with recombinant Hepatitis B vaccine for 5 days at 2-8 ℃, the adsorption rate was approximate to 50%. The experiment proves that CpG ODN could significantly enhance the immune response of HBV in mice.
出处 《免疫学杂志》 CAS CSCD 北大核心 2015年第1期53-57,共5页 Immunological Journal
基金 国家高技术研究发展计划(2012AA02A404)
关键词 CPG ODN佐剂 乙肝疫苗 免疫原性 CpG ODN Hepatitis B vaccine Immunogenicity
  • 相关文献

参考文献14

  • 1Belani CP, Nemunaitis JJ, Chachoua A, et al. Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer[J]. Cancer Biol Ther, 2013, 14(7): 557-563.
  • 2Hopkins RJ, Daczkowski NF, Kaptur PE, et al. Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers[J]. Vaccine, 2013, 31(30): 3051-3058.
  • 3Kovacs Nolan J, Mapletoft JW, Latimer L, et al. CpG oligonncleotide, host defense peptide and polyphosphazene act synergistically, inducing long-lasting, balanced immuneresponses in cattle[J]. Vaccine, 2009, 27(14): 2048-2054.
  • 4Irina Caminschi, Simone Meuter, William R, et al. DEC-25 is a cell surface receptor for CpG oligonucleotides [J]. Oncoimmundogy, 2013, 2(3): 1-2.
  • 5Jassies van der Lee A, Rutten V, Spiering R, et al. The immunostimulatory effect of CpG oligodeoxynucleotides on peripheral blood mononuclear ceils of healthy dogs and dogs with atopic dermatitis[J]. Vet J, 2014, 200(1): 103-108.
  • 6Klinman DM, Klaschik S, Tomaru K, et al. Immunostimulatory CpG oligonucleotides: effect on gene expression and utility as vaccine adjuvants[J]. Vaccine, 2010, 28(8): 1919-1923.
  • 7Michael J, McCluskie RD. Weeratna DM, et al. CpG ODN and iscomatrix adjuvant: a synergistic adjuvant combination inducing strong T-cell IFN- responses [J]. Biomed Res Int, 2013, 2013: 1-11.
  • 8Minang JT, Inglefield JR, Harris AM, et al. Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909)[J]. Vaccine, 2014, 32(50): 6847-6854.
  • 9Hanagata N. Structure-dependent immunostimulatory effect of CpG oligodeoxynueleotides and their delivery system[J]. Int J Nanomed, 2012, 7(1): 2181-2195.
  • 10Krieg AM. Therapeutic potential of Toll-like receptor 9 activation[J]. Nat Rev Drug Discov, 2006, 5(6): 471-484.

二级参考文献17

共引文献14

同被引文献35

  • 1王露露,皇甫皓月,席飞,张振江,Weldu Tesfagaber,张纪文,黄炼榆,李芳,步志高,赵东明.非洲猪瘟病毒pA104R蛋白单克隆抗体的制备与应用[J].中国预防兽医学报,2021,43(11):1214-1218. 被引量:6
  • 2曹雪涛.医学免疫学[M].北京:人民卫生出版社.2013:93-95;173-175.
  • 3Martin Fontecha A, Selmstiani S, Hopken UE, et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming[J]. J Exp Med, 2003, 198(4): 615-62 1.
  • 4Galli SJ, Nakae S, Tsai M. Mast cells in the developnlent of adaptive immune responses[J]. Nat Immunol, 2005, 6(2): 135-142.
  • 5Dudeck A, Suender CA, Kostka SL, et al. Mast cells promote Thl and Th17 responses by modulating dendritic cell maturation and function[J]. Eur J lmmunol, 2011, 41(7): 1883-1893.
  • 6Otsuka A, Kubo M, Honda T, el al. Rcquiretnent of interaction betwcen mast cells and skin dendritic cells to establish contact hypersensitivity[J]. PLoS One, 2011, 6(9): e25538.
  • 7McLachlan JB, Shelburnc CP, Harl JP, et al. Mast cell activators a new class of highly effective vaccine adjuwmts[J]. Nat Med, 2008, 14(5): 536-541.
  • 8McGowen AL, Hale LP, Shelburne CP, et al. The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen[J]. Vaccine, 2009, 27(27): 3544- 3552.
  • 9Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity[J]. Nat Rev Immunol, 2008, 8(6): 478-486.
  • 10Jawdat DM, Albert E J, Rowden G, et al. IgE-mediated mast cell activation induces Langerhans cell migration in vivo[J]. J Immunol, 2004, 173(8): 5275-5282.

引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部